嵌合抗原受体修饰T细胞治疗恶性肿瘤的研究进展  

Development of chimeric antigen receptor-modified T cells for treatment of malignances

作　　者：曹玲[1] 张毅[1] 

机构地区：[1]郑州大学第一附属医院生物细胞治疗中心,河南郑州450052

出　　处：《兰州大学学报（医学版）》2015年第1期1-8,共8页Journal of Lanzhou University（Medical Sciences）

基　　金：卫生部科研攻关基金项目(20110110001);河南省科技厅创新型科技团队项目(C20120030)

摘　　要：嵌合抗原受体(CAR)是一种重组的抗原受体,同时具有结合抗原及激活T细胞的功能。转入CAR的T细胞肿瘤细胞的杀伤不依赖于主要组织相容性复合体(MHC),并可克服肿瘤局部免疫抑制微环境和打破宿主免疫耐受态,因此CAR-T细胞免疫治疗比传统的T细胞治疗有更多的优势。基于一系列不同肿瘤表面抗原设计重组的CAR-T胞在体内外显示了明显的抗肿瘤效应,尤其是靶向CD19的CAR-T细胞已经在B细胞恶性肿瘤的临床患者中取得了良的疗效。随着CAR技术的不断优化,CAR-T细胞在肿瘤的细胞免疫治疗中必将发挥更重要的作用。Chimeric antigen receptor （CAR） is recombinant receptor that provides both antigen-binding and T cell activating functions. Cancer immunotherapy via CAR-T cells is independent of major histocompatibility complex （MHC）, moreover, CAR-T cells can overcome the immunity suppression in the microenvironment of the tumor site and break out the immunological tolerance of the host. So it has its own advantages compared with the conventional T cell-based immunotherapy. A multitude of CARs targeting an array of cell surface tumor antigens has been reported for their significant anti-tumor effect in vitro or in vivo, especially the patients with B-cell malignancies treated with CD 19-targeted CAR-T cells have got encouraging clinical bene- fits recently. CAR-T cells might play an important role in cancer immunotherapy following the optimization of the CAR technology.

关 键 词：嵌合抗原受体 T细胞 肿瘤免疫治疗 

分 类 号：R73-36[医药卫生—肿瘤]